BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19330842)

  • 1. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.
    Giltnane JM; Moeder CB; Camp RL; Rimm DL
    Cancer; 2009 Jun; 115(11):2400-9. PubMed ID: 19330842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
    Tovey S; Dunne B; Witton CJ; Forsyth A; Cooke TG; Bartlett JM
    Clin Cancer Res; 2005 Jul; 11(13):4835-42. PubMed ID: 16000581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
    Pawlowski V; Révillion F; Hebbar M; Hornez L; Peyrat JP
    Clin Cancer Res; 2000 Nov; 6(11):4217-25. PubMed ID: 11106235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.
    Chiu CG; Masoudi H; Leung S; Voduc DK; Gilks B; Huntsman DG; Wiseman SM
    Ann Surg; 2010 Jun; 251(6):1107-16. PubMed ID: 20485140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic markers in triple-negative breast cancer.
    Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
    Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR.
    Labuhn M; Vuaroqueaux V; Fina F; Schaller A; Nanni-Metellus I; Kung W; Eppenberger-Castori S; Martin PM; Eppenberger U
    Int J Biol Markers; 2006; 21(1):30-9. PubMed ID: 16711511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
    Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
    Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
    Asano T; Sato S; Yoshimoto N; Endo Y; Hato Y; Dong Y; Takahashi S; Fujii Y; Toyama T
    Jpn J Clin Oncol; 2014 Oct; 44(10):889-97. PubMed ID: 25163465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
    BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.